Brief: Clearmind Medicine Announces Exclusive Licensing Agreement For Generation 3.0 Psychedelic Compounds For The Treatment Of Mental Disorders
17/04/2024 12:50
April 17 (Reuters) - Clearmind Medicine Inc CMND.O :
* CLEARMIND MEDICINE ANNOUNCES EXCLUSIVE LICENSING AGREEMENT
FOR
GENERATION 3.0 PSYCHEDELIC COMPOUNDS FOR THE TREATMENT OF MENTAL
DISORDERS
Source text for Eikon: ID:nGNX29VvW
Further company coverage: CMND.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearmind Medicine
See all newsBrief: Clearmind Advances Dialogue With U.S. Federal Government On Psychedelic Therapies, Submitting Recommendations To FDA
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM